Genetic and other sources of variation in the activity of serum paraoxonase/diazoxonase in humans: consequences for risk from exposure to diazinon

Pharmacogenetics and Genomics

Volumn 15, Issue 1, 2005, Pages 51-60

  O'Leary, Karen A ^a   Edwards, Robert J ^a   Town, Margaret M ^a   Boobis, Alan R ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

diazinon; diazoxon; metabolism; paraoxonase; polymorphism; susceptibility

Indexed keywords

ARYLDIALKYLPHOSPHATASE; CHOLINESTERASE INHIBITOR; DIMPYLATE; PON1 PROTEIN, HUMAN; PYRIMIDINE DERIVATIVE; SODIUM CHLORIDE;

ADULT; ALLELE; ARTICLE; BLOOD; CHEMICAL MODEL; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENETICS; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; METHODOLOGY; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; RISK; TEMPERATURE; TIME; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME SUBSTRATE; EXPOSURE; NORMAL HUMAN; PH; PRIORITY JOURNAL; PROMOTER REGION; QUANTITATIVE ANALYSIS; RESTRICTION MAPPING; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE;

ADULT; ALLELES; ARYLDIALKYLPHOSPHATASE; CHOLINESTERASE INHIBITORS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIAZINON; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MODELS, CHEMICAL; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; RISK; TEMPERATURE; TIME FACTORS; VARIATION (GENETICS);

OVIS ARIES;

EID: 21944435940     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/01213011-200501000-00008     Document Type: Article

References (38)

1. International Programme on Chemical Safety (IPCS). Environmental Health Criteria No. 198: Diazinon. Geneva: World Health Organization; 1998.
2. Committee on Toxicity of Chemicals in Food, Consumer Product and the Environment. Report on Organophosphates. London: Department of Health, HMSO; 1999.
3. Statutory Instrument 1997 no. 2892. The Medicines (Veterinary Drugs) (Pharmacy and Merchants' List) (Amendment) Order 1997. London: HMSO; 1997.
4. Yuknavage KL, Fenske RA, Kalman DA, Keifer MC, Furlong CE. Simulated dermal contamination with capillary samples and field cholinesterase biomonitoring. J Toxicol Environ Health 1997; 51:35-55.
5. Norman BJ, Poore RE, Neal RA. Studies of the binding of sulfur released in the mixed-function oxidase-catalyzed metabolism of diethyl p-nitrophenyl phosphorothionate (parathion) to diethyl p-nitrophenyl phosphate (paraoxon). Biochem Pharmacol 1974; 23:1733-1744.
6. Kamataki T, Neal RA. Metabolism of diethyl p-nitrophenyl phosphorothionate (parathion) by a reconstituted mixed-function oxidase enzyme system: studies of the covalent binding of the sulfur atom. Mol Pharmacol 1976; 12:933-944.
7. Chambers JE, Carr RL. Inhibition patterns of brain acetylcholinesterase and hepatic and plasma aliesterases following exposures to three phosphorothionate insecticides and their oxons in rats. Fundam Appl Toxicol 1993; 21:111-119.
8. Li WF, Costa LG, Furlong CE. Serum paraoxonase status: a major factor in determining resistance to organophosphates. J Toxicol Environ Health 1993; 40:337-346.
9. Li WF, Furlong CE, Costa LG. Paraoxonase protects against chloropyrifos toxicity in mice. Toxicol Lett 1995; 76:219-226.
10. Furlong CE, Li WF, Brophy VH, Jarvik GP, Richter RJ, Shih DM, et al. The PON1 gene and detoxication. Neurotoxicology 2000; 21:581-587.
11. Furlong CE, Li WF, Richter RJ, Shih DM, Lusis AJ, Alleva E, Costa LG. Genetic and temporal determinants of pesticide sensitivity: role of paraoxonase (PON1). Neurotoxicology 2000; 21:91-100.
12. Costa LG, McDonald BE, Murphy SD, Omenn GS, Richter RJ, Motulsky AG, Furlong CE. Serum paraoxonase and its influence on paraoxon and chlorpyrifos-oxon toxicity in rats. Toxicol Appl Pharmacol 1990; 103:66-76.
13. Davies HG, Richter RJ, Keifer M, Broomfield CA, Sowalla J, Furlong CE. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nature Genet 1996; 14:334-336.
14. Costa LG, Li WF, Richter RJ, Shih DM, Lusis A, Furlong CE. The role of paraoxonase (PON1) in the detoxication of organophosphates and its human polymorphism. Chem Biol Interact 1999; 119-120:429-438.
15. Furlong CE, Li WF, Costa LG, Richter RJ, Shih DM, Lusis AJ. Genetically determined susceptibility to organophosphorus insecticides and nerve agents: developing a mouse model for the human PON1 polymorphism. Neurotoxicology 1998; 19:645-650.
16. Marchesani M, Hakkarainen A, Tuomainen TP, Kaikkonen J, Pukkala E, Uimari P, et al. New paraoxonase 1 polymorphism I102 V and the risk of prostate cancer in Finnish men. J Natl Cancer Inst 2003; 95:812-818.
17. Adkins S, Gan KN, Mody M, La Du BN. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet 1993; 52:598-608.
18. Humbert R, Adler DA, Distecke CM, Hassett C, Omiecinski CJ, Furlong CE. The molecular basis of the human serum paraoxonase activity polymorphism. Nature Genet 1993; 3:73-76.
19. Brophy VH, Jarvik GP, Richter RJ, Rozek LS, Schellenberg GD, Furlong CE. Analysis of paraoxonase (PON1) L55M status requires both genotype and phenotype. Pharmacogenetics 2000; 10:453-460.
20. Leviev I, Negro F, James RW. Two alleles of the human paraoxonase gene produce different amounts of mRNA. An explanation for differences in serum concentrations of paraoxonase associated with the (Leu-Met54) polymorphism. Arterioscler Thromb Vasc Biol 1997; 17:2935-2939.
21. Blatter-Garin M-C, James RW, Dussoix P, Blanché H, Passa P, Froguel P, Ruiz J. Paraoxonase polymorphism Met-Leu 54 is associated with modified serum concentrations of the enzyme. J Clin Invest 1997; 99:62-66.
22. Furlong CE, Richter RJ, Seidel SL, Motulsky AG. Role of genetic polymorphism of human plasma paraoxonase/arylesterase in hydrolysis of the insecticide metabolites chlorpyrifos oxon and paraoxon. Am J Hum Genet 1988; 43:230-238.
23. Smolen A, Eckerson HW, Gan KN, Hailat N, La Du BN. Characteristics of the genetically determined allozymic forms of human serum paraoxonase/arylesterase. Drug Metab Dispos 1991; 19:107-112.
24. Eckerson HW, Wyte CM, La Du BN. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 1983; 35:1126-1138.
25. Geldmacher-von Mallinckrodt M, Diepgen TL. The human serum paraoxonase-polymorphism and specificity. Toxicol Environ Chem 1988; 18:79-196.
26. Li WF, Costa LG, Richter RJ, Hagen T, Shih DM, Tward A, et al. Catalytic efficiency determines the in-vivo efficacy of PON1 for detoxifying organophosphorus compounds. Pharmacogenetics 2000; 10:767-779.
27. Brophy VH, Hastings MD, Clendenning JB, Richter RJ, Jarvik GP, Furlong CE. Polymorphisms in the human paraoxonase (PON1) promoter. Pharmacogenetics 2001; 11:77-84.
28. Leviev I, James RW. Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler Thromb Vasc Biol 2000; 20:516-521.
29. Deakin S, Leviev I, Brulhart-Meynet MC, James RW. Paraoxonase-1 promoter haplotypes and serum paraoxonase: a predominant role for polymorphic position −107, implicating the Sp1 transcription factor. Biochem J 2003; 372:643-649.
30. Brophy VH, Jampsa RL, Clendenning JB, McKinstry LA, Jarvik GP, Furlong CE. Effects of 5′ regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. Am J Hum Genet 2001; 68:1428-1436.
31. Suehiro T, Nakamura T, Inoue M, Shiinoki T, Ikeda Y, Kumon Y, et al. A polymorphism upstream from the human paraoxonase (PON1) gene and its association with PON1 expression. Atherosclerosis 2000; 150:295-298.
32. Cherry N, Mackness M, Durrington P, Povey A, Dippnall M, Smith T, Mackness B. Paraoxonase (PON1) polymorphisms in farmers attributing ill health to sheep dip. Lancet 2002; 359:763-764.
33. Mackness B, Durrington P, Povey A, Thomson S, Dippnall M, Mackness M, et al. Paraoxonase and susceptibility to organophosphorus poisoning in farmers dipping sheep. Pharmacogenetics 2003; 13:81-88.
34. Kappers WA, Edwards RJ, Murray S, Boobis AR. Diazinon is activated by CYP2C19 in human liver. Toxicol Appl Pharmacol 2001; 177:68-76.
35. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 1998; 101:1581-1590.
36. Herrmann SM, Blanc H, Poirier O, Arveiler D, Luc G, Evans A, et al. The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM Study. Atherosclerosis 1996; 126:299-303.
37. Schmidt H, Schmidt R, Niederkorn K, Gradert A, Schumacher M, Watzinger N, et al. Paraoxonase PON1 polymorphism leu-Met54 is associated with carotid atherosclerosis: results of the Austrian Stroke Prevention Study. Stroke 1998; 29:2043-2048.
38. HernÁndez AF, Mackness B, Rodrigo L, Lopez O, Pla A, Gil F, et al. Paraoxonase activity and genetic polymorphisms in greenhouse workers with long term pesticide exposure. Hum Exp Toxicol 2003; 22:565-574.